Fennec Pharmaceuticals Inc. (FENC) intrinsic value & 10-year financials
Fennec Pharmaceuticals Inc. (FENC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 204.7% a year to $44.6M, with an average return on invested capital of 43.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $9.98
- Market cap
- $285.2M
- Revenue (FY2025)
- $44.6M
- Revenue growth (10-yr CAGR)
- 204.7%
- ROIC (10-yr avg)
- 43.0%
- Free cash flow (FY2025)
- —
FENC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $44.6M | -$9.7M | -$0.34 | — | -14.1% | 47.7% |
| FY2024 | $47.5M | -$436.0K | -$0.02 | — | 5.4% | -72.1% |
| FY2023 | $23.8M | -$16.0M | -$0.60 | — | -53.7% | -697.9% |
| FY2022 | $1.8M | -$23.7M | -$0.90 | — | -1276.9% | 1564.3% |
| FY2021 | — | -$17.3M | -$0.00 | — | — | -76.8% |
| FY2020 | $170.0K | -$18.1M | -$0.00 | — | -10520.6% | -87.4% |
| FY2019 | $0 | -$12.8M | — | — | — | -78.4% |
| FY2018 | $0 | -$9.9M | — | — | — | -43.3% |
| FY2017 | $0 | -$7.0M | — | — | — | -45.8% |
| FY2016 | $0 | -$2.8M | — | — | — | -80.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
FENNEC PHARMACEUTICALS INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
FENNEC PHARMACEUTICALS INC. has historically struggled to out-earn its cost of capital, averaging just -42.8% ROIC.
Over the decade, FENNEC PHARMACEUTICALS INC. shows that management has aggressively returned capital to shareholders by retiring 99.8% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, FENNEC PHARMACEUTICALS INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-11.29 per share.